D4S:FRA
Daiichi Sankyo Co Ltd
13,57 €
arrow_downward
-2,96%(-0,41) 1d
30 d’abr., 22:00:00 GMT+2 · EUR
search
Tots els símbols
1d
5d
1m
6m
YTD
1a
5a
Màx.
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a D4S...
Obre
13,57 €
Alt
13,57 €
Baix
13,57 €
Capitalització borsària
4,96 B
Volum mitjà
194,00
Volum
0,00
Alt 52 setmanes
23,91 €
Baix 52 setmanes
13,57 €
Nombre d'empleats
20 k
Notícies
De fonts en tot el web
The Motley Fool
·
fa 2 minuts
S&P 500 vs. Gold: Warren Buffett Said Buy One and Forget the Other
MarketBeat
·
fa 4 minuts
Roper Technologies, Inc. (NASDAQ:ROP) Short Interest Update
bloomingbit
·
fa 6 minuts
Alphabet, Amazon Earnings Surprise Lifts S&P 500, Nasdaq to Record Highs
Perfil
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey.
Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
Sobre Daiichi Sankyo Co Ltd
Conseller delegatHiroyuki Okuzawa
Empleats19,8 k
Fundació28 de set. 2005
Seu principalChūō, Tòquio, Japó
Sector-
Lloc webdaiichisankyo.co.jp
El contingut d'IA pot incloure errors. Més informació